Bibliografia UJ CM




Zapytanie: DREYLING MARTIN
Liczba odnalezionych rekordów: 12



Przejście do opcji zmiany formatu | Wyświetl/ukryj etykiety | Wersja do druku | | | Nowe wyszukiwanie
1/12
Toby A. Eyre, Nirav N. Shah, Martin Dreyling, Wojciech Jurczak, Yucai Wang, Chan Y. Cheah, Yuqin Song, Mitul Gandhi, Christopher Chay, Jeff Sharman, David J. Andorsky, Hannah M. Messersmith, Amy S. Ruppert, Valerie A. Muthig, Rodrigo Ito, Michael L. Wang.
BRUIN MCL-321 : phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma
Future Oncology
2022 : Vol. 18, nr 36, s. 3961-3969, il., bibliogr. 39 poz., sum.
Autor korespondencyjny: Toby A Eyre
Online First 2022-11-15
Open Access Creative Commons Attribution License CC-BY-NC-ND 4.0.

p-ISSN: 1479-6694

AZ
ORG
AIF
IF: 3.300
Adres url:
Streszczenie w PubMed:
2/12
Michael L. Wang, Wojciech Jurczak, Mats Jerkeman, Judith Trotman, Pier L. Zinzani, David Belada, Carola Boccomini, Ian W. Flinn, Pratyush Giri, Andre Goy, Paul A. Hamlin, Olivier Hermine, José-Ángel Hernández-Riva, Xiaonan Hong, Seok Jin Kim, David Lewis, F.R.C. Path, Yuko Mishima, Muhit Özcan, Guilherme F. Perini, Christopher Pocock, Yuqin Song, Stephen E. Spurgeon, John M. Storring, Jan Walewski, Jun Zhu, Rui Qin, Todd Henninger, Sanjay Deshpande, Angela Howes, Steven Le Gouill, Martin Dreyling.
Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma
New England Journal of Medicine
2022 : Vol. 386, nr 26, s. 2482-2494, il., bibliogr. 24 poz., abstr.
Autor korespondencyjny: Michael L. Wang.
p-ISSN: 0028-4793
e-ISSN: 1533-4406

AZ
ORG
AIF
IF: 158.500
Adres url:
Streszczenie w PubMed:
3/12
Johannes Duell, Kami J. Maddocks, Eva Gonzalez-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Ales Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc Andre, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
2021 : Vol. 106, nr 9, s. 2417-2426, il., bibliogr. 18 poz.
Autor korespondencyjny: Gilles Salles.
p-ISSN: 0390-6078

AZ
ORG
AIF
IF: 11.049
Adres url:
Streszczenie w PubMed:
4/12
Lucia Morello, Sara Sattotti, Laura Giordano, Mats Jerkeman, Tom van Meerten, Katarzyna Krawczyk, Filipa Moita, Dario Marino, Simone Ferrero, Michał Szymczyk, Igor Aurer, Tarec Christoffer El-Galaly, Alice Di Rocco, Carlo Visco, Giuseppe Carli, Irene Defrancesco, Carmelo Carlo-Stella, Martin Dreyling, Armando Santoro, Luca Arcaini.
Mantle cell lymphoma of mucosa-associated lymphoid tissue : A European Mantle Cell Lymphoma Network Study
HemaSphere
2020 : Vol. 4, nr 1, il., bibliogr. 21 poz., abstr.
Autor korespondencyjny: Luca Arcaini
p-ISSN: 2572-9241

AZ
ORG
APZ
Adres url:
5/12
Gilles Salles, Johannes Duell, Eva González Barca, Olivier Tournilhac, Wojciech Jurczak, Anna Marina Liberati, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Marc André, Nagesh Kalakonda, Martin Dreyling, Johannes Weirather, Maren Dirnberger-Hertweck, Sumeet Ambarkhane, Günter Fingerle-Rowson, Kami Maddocks.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND) : a multicentre, prospective, single-arm, phase 2 study.
Lancet. Oncology
2020 : Vol. 21, nr 7, s. 978-988, il., bibliogr. 30 poz., sum.
Autor korespondencyjny: Gilles Salles.
p-ISSN: 1470-2045

AZ
ORG
AIF
IF: 41.316
Adres url:
Streszczenie w PubMed:
6/12
Georg Hess, Simon Rule, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Dolores Caballero, Cristina Joao, Mathias Witzens-Harig, Isabelle Bence-Bruckler, Seok-Goo Cho, Wenjiong Zhou, Jenna D. Goldberg, Cristina Trambitas, Christopher Enny, Jessica Vermeulen, Shana Traina, Chiun-Fang Chiou, Joris Diels, Martin Dreyling.
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Leukemia & Lymphoma
2017 : Vol. 58, nr 12, s. 2824-2832
Autor korespondencyjny: Georg Hesss.
p-ISSN: 1042-8194

AZ
ORG
AIF
IF: 2.644
Adres url:
Streszczenie w PubMed:
DOI:
7/12
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Marek Trneny, Fritz Offner, Dolores Caballero, Cristina Joao, Mathias Witzens-Harig, Georg Hess, Isabelle Bence-Bruckler, Seok-Goo Cho, John Bothos, Jenna D. Goldberg, Christopher Enny, Shana Traina, Sriram Balasubramanian, Nibedita Bandyopadhyay, Steven Sun, Jessica Vermeulen, Aleksandra Rizo, Simon Rule.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Lancet
2016 : Vol. 387, nr 10020, s. 770-778, il., bibliogr. 29 poz., sum.
p-ISSN: 0140-6736

AZ
ORG
AIF
IF: 47.831
Adres url:
Streszczenie w PubMed:
8/12
Peter Martin, Kami Maddocks, John P. Leonard, Jia Ruan, Andre Goy, Nina Wagner-Johnston, Simon Rule, Ranjana Advani, David Iberri, Tycel Phillips, Stephen Spurgeon, Eliana Kozin, Katherine Noto, Zhengming Chen, Wojciech Jurczak, Rebecca Auer, Ewa Chmielowska, Stephan Stilgenbauer, Johannes Bloehdorn, Craig Portell, Michael E. Williams, Martin Dreyling, Paul M. Barr, Selina Chen-Kiang, Maurizio DiLiberto, Richard R. Furman, Kristie A. Blum.
Postibrutinib outcomes in patients with mantle cell lymphoma.
Blood
2016 : Vol. 127, nr 12, s. 1559-1563, il., bibliogr. 14 poz., abstr.
p-ISSN: 0006-4971

AZ
ORG
AIF
IF: 13.164
Adres url:
Streszczenie w PubMed:
9/12
Michael L. Wang, Kristie A. Blum, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Liang Zhang, Linda Baher, Mei Cheng, Dana Lee, Darrin M. Beaupre, Simon Rule.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results.
Blood
2015 : Vol. 126, nr 6, s. 739-745, il., bibliogr. 14 poz., abstr.
p-ISSN: 0006-4971

AZ
ORG
AIF
IF: 11.847
Adres url:
Streszczenie w PubMed:
10/12
Ajay K. Gopal, Brad S. Kahl, Sven Vos, de, Nina D. Wagner-Johnston, Stephen J. Schuster, Wojciech J. Jurczak, Ian W. Flinn, Christopher R. Flowers, Peter Martin, Andreas Viardot, Kristie A. Blum, Andre H. Goy, Andrew J. Davies, Pier Luigi Zinzani, Martin Dreyling, Dave Johnson, Langdon L. Miller, Leanne Holes, Daniel Li, Roger D. Dansey, Wayne R. Godfrey, Gilles A. Salles.
PI3KΔ inhibition by idelalisib in patients with relapsed indolent lymphoma.
New England Journal of Medicine
2014 : Vol. 370, nr 11, s. 1008-1018, il., bibliogr., abstr.
p-ISSN: 0028-4793

AZ
ORG
AIF
IF: 55.873
Adres url:
11/12
Michael L. Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer, Bras S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Y. Chang, Darrin M. Beaupre, Lori A. Kunkel, Kristie A. Blum.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
New England Journal of Medicine
2013 : Vol. 369, nr 6, s. 507-516, il., bibliogr. 29 poz., abstr.
p-ISSN: 0028-4793

AZ
ORG
AIF
IF: 54.420
Adres url:
12/12
Martin Dreyling, Eva Hoster, Silvia Bea, Elena Hartmann, Heike Horn, Grit Hutter, Itziar Salaverria, Christiane Pott, Marek Trneny, Steven Le Gouill, Sergio Cortelazzo, Michal Szymczyk, Wojciech Jurczak, Ofer Sphilberg, Vincent Ribrag, Olivier Hermine.
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL) : minutes of the 9th European MCL Network conference.
Leukemia & Lymphoma
2010 : Vol. 51, nr 9, s. 1612-1622, bibliogr. 36 poz.
AZ
POG
AIF
IF: 2.492
  Wyświetl ponownie stosując format:
Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ